1. DL Zhu, et al. Insulin degludec in people with type 2 diabetes in China: a non‑interventional, retrospective chart review study (CN-TREAT). Oral Poster presented at IDF World Diabetes Congress 2022. 2. Novo Nordisk...
1. DL Zhu, et al. Insulin degludec in people with type 2 diabetes in China: a non‑interventional, retrospective chart review study (CN-TREAT). Oral Poster presented at IDF World Diabetes Congress 2022. 2. Novo Nordisk. Tresiba®. Available at: https://www.nmpa.gov.cn/datasearch/sear...
[1]、Phillips LS, et al. We can change the natural history of type 2 diabetes. Diabetes Care. 2014;37(10):2668-2676. [2]、Wangnoo SK, et al. Indian J Endocrinol Metab. 2014 Mar;18(2):166-74. [3]、 成人2型糖尿...
Ahren B. Vildagliptin: novel pharmacological approach to treat type 2 diabetes. Therapy. 2008; 5 :79–90.Bo Ahrén . (2008) Vildagliptin: novel pharmacological approach to treat Type 2 diabetes. Therapy 5 , 79-90 Online publication date: 1-Jan-2008. /...
Metformin salts of 2,4-thiazolidinediones are described for the treatment of diabetes mellitus Type2, gestational diabetes, polycystic ovary syndrome, non-alcoholic fatty liver disease, coronary artery disease, pancreatic cancer, premature puberty, and other diseases which manifest insulin resistance.Om P...
USE OF TGF-BETA ANTAGONISTS OF TREAT TYPE-2 DIABETESMethod and compositions for treating type-2 diabetes in a subject are provided comprising administering to the subject an amount of an inhibitor of a TGF-beta.CAI, Dongsheng
1. Zinman B, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N...
Lixisenatide,a drug developed to treat type2 diabetes,shows neuroprotective effects in a mouse model of Alzheimer’’s disease. Mc Clean PL,Holscher C. Neuropharmacology . 2014MCCLEAN P L, HOLSCHER C. Lixisenatide, a drug developed to treat type 2 diabetes, shows neuroprotective effects in a ...
[15]. ANNA P. GUERRERO-CASTILLO, er al. Diabetes 20 June 2023; 72 (Supplement_1): 885–P. [16]. Gonzalez Perez, A., et al. Cardiovascular and renal outcomes among patients with type 2 diabetes using SGLT2 inhib...
16. 任明慧,张力辉. SGLT2 抑制剂应用于 2型糖尿病合并肾功能不全患者的心血管肾脏结局及安全性的系统评价和 meta 分析. 2023. CSE. 17. Henry RR, Murray AV, Marmolejo MH, et al. Dapagliflozin, metformin XR, or both: initial phar...